Diego A. Díaz-García, Medical Oncologist, CEO, and Founder of CánCare – Advanced Oncology Specialty, shared a post on X about a paper by Matthias Hinterndorfer et al. published on the Nature Reviews Cancer:
“Targeted protein degradation is reshaping cancer therapy:
From PROTACs to molecular glues, new tools are enabling selective elimination of oncogenic proteins, with clinical impact on the horizon.”
Title: Targeted protein degradation for cancer therapy
Authors: Matthias Hinterndorfer, Valentina Spiteri, Alessio Ciulli, Georg Winter
You can read the Full Article on the Nature Reviews Cancer.
More posts featuring Cancer Therapy on OncoDaily.
